The ongoing pursuit of neuroprotective therapies in Parkinson disease
Crossref DOI link: https://doi.org/10.1038/nrneurol.2014.226
Published Online: 2014-12-02
Published Print: 2015-01
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Athauda, Dilan
Foltynie, Thomas
Text and Data Mining valid from 2014-12-02
Article History
First Online: 2 December 2014
Competing interests
: T.F. has received honoraria from Abbvie, Genus, Medtronic, Novartis, St. Jude Medical and Teva. D.A. declares no competing interests.